DVAX Stock Overview
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for DVAX from our risk checks.
Dynavax Technologies Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.17 |
| 52 Week High | US$15.15 |
| 52 Week Low | US$10.06 |
| Beta | 1.28 |
| 1 Month Change | -9.70% |
| 3 Month Change | -16.14% |
| 1 Year Change | 7.20% |
| 3 Year Change | 6.79% |
| 5 Year Change | 66.72% |
| Change since IPO | -88.12% |
Recent News & Updates
Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06
Recent updates
Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Dynavax: A Coronavirus Growth Story
Jan 17Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 18The Momentum Investor: Spotlight On Dynavax Technologies
Oct 25Dynavax And TLR Biology: Long-Delayed But Outstanding Success
Oct 16These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well
Oct 02Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts
Aug 10Dynavax: Earnings This Year Ought To Surprise To The Upside
Aug 01Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
May 30Dynavax shares down 6% on launch of $200M debt offering
May 10Shareholder Returns
| DVAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.5% | 0.4% | 1.0% |
| 1Y | 7.2% | 0.9% | 21.9% |
Return vs Industry: DVAX exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: DVAX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| DVAX volatility | |
|---|---|
| DVAX Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DVAX's share price has been volatile over the past 3 months.
Volatility Over Time: DVAX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 408 | Ryan Spencer | www.dynavax.com |
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.
Dynavax Technologies Corporation Fundamentals Summary
| DVAX fundamental statistics | |
|---|---|
| Market cap | US$1.46b |
| Earnings (TTM) | -US$6.39m |
| Revenue (TTM) | US$232.28m |
6.3x
P/S Ratio-228.8x
P/E RatioIs DVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DVAX income statement (TTM) | |
|---|---|
| Revenue | US$232.28m |
| Cost of Revenue | US$102.48m |
| Gross Profit | US$129.81m |
| Other Expenses | US$136.19m |
| Earnings | -US$6.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 55.88% |
| Net Profit Margin | -2.75% |
| Debt/Equity Ratio | 35.8% |
How did DVAX perform over the long term?
See historical performance and comparison